Alzheimer’s Disease: Molecular Pathogenesis and Therapy
Alzheimer’s disease (AD) is the most common form of dementia and currently afflicts more than 5 million Americans. However, no satisfactory treatment is available. In Dr. Fukuchi’s laboratory, the pathogenesis of AD is investigated and innovative preventive and therapeutic measures against AD are being developed. This research is advancing novel vaccination modalities against AD and optimizing the efficacy and safety of gene therapy modalities against AD. Dr. Fukuchi’s research also focuses on deciphering the molecular mechanism by which the immune system contributes to the development and progression of AD. To accomplish these research goals, Dr. Fukuchi takes interdisciplinary approaches using molecular biology, transgenic/gene targeting approach, immunology, gene therapy, and behavioral neuroscience.
Ken-ichiro Fukuchi, M.D., Ph.D., joined the Department of Cancer Biology and Pharmacology in 2005. He is a neuroscientist, molecular biologist and trained as a geriatrician. He has made many significant contributions and advances in understanding the molecular mechanisms underlying the development of AD, and he is a pioneer in immunogene therapy for AD. His research accomplishment in AD led to the Zenith Award from the Alzheimer’s Association, which is given to investigators who contributed significantly to AD research.